



**TAGORE MEDICAL COLLEGE AND HOSPITAL**  
 Recognized by Medical Council of India, New Delhi  
 Affiliated to the Tamil Nadu Dr. MGR Medical University, Chennai  
 Rathinamangalam, Melakottaiyur post, Chennai – 600127.  
**Phase-II MBBS Time Table**

Day	08.00-11.00 am	11.00-12.00 noon	12.00-01.00 pm	1.00-1.30pm	1.30-2.30 pm (L) 1.30-3.30 pm (P)	1.30-2.30 pm (L) 1.30-3.30 pm (P)
1	CP	PA 1.1, 1.2, 1.3 Introduction (L)	PH 1.1, 1.9 principles, nomenclature of drugs (L)	LUNCH BREAK	PA 1.1 & 1.3 Department tour (P)	PH 1.3 Drug formulations (P)
2		MI1.1 Introduction & History (L)	PA 2.1,2.2, 2.6 Cell injury & adaptation (L)		PA 1.1 & 1.3 Department tour (P)	PH 1.3 Drug formulations (P)
3		PH 1. 11 Routes of drug (L)	IM26.1 & IM 26.6 role of physician (L)		MI 1.1 Microscopes(P)	CM1.3 Agent, host and environment factors
4		MI1.1 Taxonomy(L)	SU 1.1 Homeostatis (L)		MI 1.1 Microscopes(P)	CM1.3 Agent, host and environment factors
5		PH 1.4 Pharmacokinetics (L)	OG2.1 Anatomy of the female reproductive tract (Basic anatomy and embryology (L)		PA 2.3,2.5 accumulation & calcification (L)	MI1.1 Morphology of bacteria(L)
6		AET-CM-2.1	CM1.1 Concepts of Public Health (L)		FM1.1 Introduction to FM (L)	SPORTS

Day	08.00-11.00 am	11.00-12.00 noon	12.00-01.00 pm	1.00-1.30pm	1.30-2.30 pm (L) 1.30-3.30 pm (P)	1.30-2.30 pm (L) 1.30-3.30 pm (P)
7	CP	PA 2.4 Necrosis (L)	PH 1.4 Pharmacokinetics (L)	LUNCH BREAK	PA 2.3 2.5 2.6 Intracellular accumulation, Gangrene & Adaptation(DOAP)	PH 2.1 Dosage forms DOAP (P)
8		MI1.1 Physiology of bacteria(T)	PA 2.7 Apoptosis ageing (L)		PA 2.3 2.5 2.6 Intracellular accumulation, Gangrene & Adaptation(DOAP)	PH 2.1 Dosage forms DOAP (P)
9		PH 1.4 Pharmacokinetics (L)	IM14.5,14.13 Nutritional disorders		MI 1.1 Diagnostic methods of bacterial infections (P)	FM1.11 Death Certificate (P)
10		MI1.1 Culture methods & culture media(L)	SU 1.3 Perioperative care (L)		MI 1.1 Diagnostic methods of bacterial infections (P)	FM1.11 Death Certificate (P)
11		PH 1.5 Pharmacodynamics (L)	OG3.1 Physiology of conception (L)		PA 3.1 Amyloidosis (L)	MI1.1 Bacterial genetics(T)
12		AET-CM-2.1	CM1.2 Determinants of Health (L)		FM1.2 History of FM (L)	PM 2.1 MI Infection control (L)

Day	08.00-11.00 am	11.00-12.00 noon	12.00-01.00 pm	1.00-1.30pm	1.30-2.30 pm (L) 1.30-3.30 pm (P)	1.30-2.30 pm (L) 1.30-3.30 pm (P)
13	CP	PA 4.1, 4.2 Intro Acute Inflammation (L)	PH 1.5 Pharmacodynamics (L)	LUNCH BREAK	PA 2.8, 3.2 Cell injury in organs - Gross & M/E & Amyloidosis (DOAP)	PH 2.3 IV setup DOAP (P)
14		MI1.1 Microbial pathogenesis(SDL)	PA 4.3 Chronic Inflammation (L)		PA 2.8, 3.2 Cell injury in organs - Gross & M/E & Amyloidosis (DOAP)	PH 2.3 IV setup DOAP (P)
15		PH 1.5 & 1.2 Pharmacodynamics (L)	IM 4.3 & IM 4.4 Approach to fever(L)		MI 1.1 Diagnostic methods of viral infections (P)	AET-FM-2.2
16		MI1.1 Overview of bacterial infections(L)	SU 2.1 Shock (L)		MI 1.1 Diagnostic methods of viral infections (P)	AET-FM-2.2
17		PA 4.3 Chronic Inflammation (L)	CM1.4 Natural History of disease (L)		FM1.3 Legal Procedures (L)	LUNCH

Day	08.00-11.00 am	11.00-12.00 noon	12.00-01.00 pm	1.00-1.30pm	1.30-2.30 pm (L) 1.30-3.30 pm (P)	1.30-2.30 pm (L) 1.30-3.30 pm (P)
18	CP	PA 5.1 wound Healing (L)	PH 1.59 EBM, FDC (L)	LUNCH BREAK	PA 4.4 Acute & Chronic Inflammation Gross & M/E (DOAP)	PH 2.3 IV setup DOAP (P)
19		MI1.1 Normal flora(S)	PA 6.1, 6.2 Edema, Hyperemia, Congesion (L)		PA 4.4 Acute & Chronic Inflammation Gross & M/E (DOAP)	PH 2.3 IV setup DOAP (P)
20		PH PH1.6, 1.7 PV, ADR (L)	IM 21.1APPROACH TO THE PATIENT STABILISATION IN POISONING (L)		MI 1.1 Diagnostic methods of parasitic infections (P)	AET-FM-2.3
21		MI1.1 Overview of viral infections(L)	SU 3.1 Blood Transfusion (L)		MI 1.1 Diagnostic methods of parasitic infections (P)	AET-FM-2.3
22		1.8 Drug interactions (T)	OG4.1 Development of the fetus and the placenta (L)		PA 6.4 Thrombosis (L)	MI1.1 Overview of parasitic infections(L)



Day	08.00-11.00 am	11.00-12.00 noon	12.00-01.00 pm	1.00-1.30pm	1.30-2.30 pm (L) 1.30-3.30 pm (P)	1.30-2.30 pm (L) 1.30-3.30 pm (P)
23	CP	PA 6.5, 6.6 Embolism, Ischemia Infarct (L)	PH 1.60 PG/PE (T)	LUNCH BREAK	PA 6.7 Infarct Gross & M/E (DOAP)	PH 3.4 ADR reporting (P)
24		MI1.1 Overview of fungal infections(L)	PA 6.3 Shock (S)		PA 6.7 Infarct Gross & M/E (DOAP)	PH 3.4 ADR reporting (P)
25	CP	MI1.3 Epidemiology of infections(I) CM 8.1	SU 4.2 Burns (L)	LUNCH BREAK	MI 1.1 Diagnostic methods of fungal infections (P)	CM1.5 Intervention and levels of prevention
26		PH 1.16 Hist/Antihist (L)	OG6.1 Diagnosis of pregnancy (L)		MI 1.1 Diagnostic methods of fungal infections (P)	CM1.5 Intervention and levels of prevention
27	PH 1.5 Clinical Pharmacology charts (T)	CM1.6 Health Promotion IEC , BCC (L)	FM1.4 Legal Procedures (L)		SPORTS	

Day	08.00-11.00 am	11.00-12.00 noon	12.00-01.00 pm	1.00-1.30pm	1.30-2.30 pm (L) 1.30-3.30 pm (P)	1.30-2.30 pm (L) 1.30-3.30 pm (P)
28		PA 7.1 Intro Neoplasia (T)	PH 1.16 Serotonin (L)		PA 6.7 Congestion Gross & M/E (DOAP)	PH 1.12 Posology (I) PE (P)
29		MI1.4 Sterilization(L)	PA 7.2 Molecular basis Ca (L)		PA 6.7 Congestion Gross & M/E (DOAP)	PH 1.12 Posology (I) PE (P)

30	CP	PH 1.16 Prostaglandins (L)	MI1.4 Disinfection(L)	LUNCH BREAK	MI 1.6 Antibiotic sensitivity tests (P)	FM2.29 Court Procedure (P)
31		MI1.6 Antimicrobial agents&antibiotic stewardship(I) PH 1.43	PM 2.1 MI Infection control (Hospital visit)		MI 1.6 Antibiotic sensitivity tests (P)	FM2.29 Court Procedure (P)
32		PH 1.16 NSAIDS (L)	MI1.7 Immunity(L)		PA 7.3 Carcinogens Carcinogenesis (L)	PM 2.1 MI Infection control -debriefing (L)
33	AET-CM-2.4		MI1.7 Components of immune system(T)		PM 2.2 CM Emergence and Re-emergence of microbes (Self study/ individual/ small group assignment)	PM 2.2 CM Emergence and Re-emergence of microbes (Self study/ individual/ small group assignment)

Day	08.00-11.00 am	11.00-12.00 noon	12.00-01.00 pm	1.00-1.30pm	1.30-2.30 pm (L) 1.30-3.30 pm (P)	1.30-2.30 pm (L) 1.30-3.30 pm (P)
34		PA 7.4, 7.5 Paraneoplastic Tumor Immunology (L)	PH 1.16 NSAID (L)		PA 7.1 Neoplasia Gross & M/E (DOAP)	PH 2.4 Posology DOAP (P)
35		MI1.8 ANTIGEN(L)	PA 8.1, 8.2, 8.3 Basic Cytology (T)		PA 7.1 Neoplasia Gross & M/E (DOAP)	PH 2.4 Posology DOAP (P)

36	CP	PH 1.16 Drugs for RA (L)	MI1.8 Antibody(L)	<b>LUNCH BREAK</b>	MI 1.5 CSSD visit (P)	CM1.9 Effective Communication skill in a simulated environment
37		MI1.8 Complement (SDL)	PM 2.2 CM (Exploratory and interactive theory session)		MI 1.5 CSSD visit (P)	CM1.9 Effective Communication skill in a simulated environment
38		PH 1.16 Drugs for gout (T)	MI1.8 Antigen antibody reactions - Part 1(L)		AET-CM-2.4	

Day	08.00-11.00 am	11.00-12.00 noon	12.00-01.00 pm	1.00-1.30pm	1.30-2.30 pm (L) 1.30-3.30 pm (P)	1.30-2.30 pm (L) 1.30-3.30 pm (P)
39	CP	MI1.8 Antigen antibody reactions - Part II(L)	PH 1.14 Cholinergics (L)	<b>LUNCH BREAK</b>	PA 8.3 FNAC & Staining DOAP	PH 2.4 Posology DOAP (P)
40		MI1.8 Immune response(L)	PA 9.1, 9.3 Intro & HLA (L)		PA 8.3 FNAC & Staining DOAP	PH 2.4 Posology DOAP (P)
41		PH 1.14 Anticholinergics (S)	IM20.3,20.7 SNAKE BITE(L)		MI 1.5 Application of sterilisation & Disinfection in clinical & surgical practice (P)	FM2.30 Medico Legal updates (P)
42		PA 9.2 Hypersensitivity (I) MI	SU 5.1 Wound Healing (L)		MI 1.5 Application of sterilisation & Disinfection in clinical & surgical practice (P)	FM2.30 Medico Legal updates (P)

43		PH 1.13 Adrenergic (L)	OG7.1 Maternal Changes in pregnancy (L)		PA 9.2 /MI 1.10 Hypersensitivity (I) MI	MI1.10 Hypersensitivity -I (L)
----	--	------------------------	---	--	---	--------------------------------

Day	08.00-11.00 am	11.00-12.00 noon	12.00-01.00 pm	1.00-1.30pm	1.30-2.30 pm (L) 1.30-3.30 pm (P)	1.30-2.30 pm (L) 1.30-3.30 pm (P)
44	CP	MI1.10 Hypersensitivity -II(L)	PH 1.13 Alpha blockers (L)	LUNCH BREAK	PA 8.3 FNAC & Staining DOAP	PH 2.2 Prepare ORS DOAP (P)
45		PA 9.4, 9.5, 9.7 auto immunity, SLE, others (L)	MI1.10 Autoimmunity (L)		PA 8.3 FNAC & Staining DOAP	PH 2.2 Prepare ORS DOAP (P)
46		PH 1.13 Beta blockers (L)	IM1.1, 1.5-1.7 HEART FAILURE (L)		MI 1.8 Interpretation of antigen-antibody reactions - Part I (P)	CM1.10 Doctor patient relationship
47		PM 2.2 CM (Factors responsible for emerging or reemerging infectious disease)	SU 5.4 Medico Legal Aspects of wound (L)		MI 1.8 Interpretation of antigen-antibody reactions - Part I (P)	CM1.10 Doctor patient relationship
48	AET-PATH-2.5	CM1.7 Health Indicators (L)	FM1.5 Legal Procedures (L)	LUNCH	SPORTS	




Day	08.00-11.00 am	11.00-12.00 noon	12.00-01.00 pm	1.00-1.30pm	1.30-2.30 pm (L) 1.30-3.30 pm (P)	1.30-2.30 pm (L) 1.30-3.30 pm (P)
49	CP	MI1.10 Immunodeficiency (L)	PH 1.42 General principles chemotherapy (L)	LUNCH BREAK	PA 9.4 & 9.5 Auto immune disorders (D)	PH 3.7 Prepare EML (I) CM 19.1 (P)
50		PA 9.6 HIV (L)	PA 10.2, 10.3 Cysticercosis, Leprosy (SDL)		PA 9.4 & 9.5 Auto immune disorders (D)	PH 3.7 Prepare EML (I) CM 19.1 (P)
51		PH 1.43 Rational use of antibiotics (SDL)	IM 17.7 17.13 Meningitis		MI 1.8 Interpretation of antigen-antibody reactions - Part II (P)	FM2.31 Autopsy Demo (P)
52		PA 10.1 Malaria (I) MI 2.5	SU 6.1 Surgical Infections (L)		MI 1.8 Interpretation of antigen-antibody reactions - Part II (P)	FM2.31 Autopsy Demo (P)
53		PH 1.42 Penicillins (L)	OG8.1 Antenatal Care (L)		PA 11.1 mutations in childhood (S)	1.10 Prescription writing (L)
54	AET-PATH-2.5	CM1.8 Demographic profile of India (L)	FM1.6 Legal Procedures (L)		PM 2.2 CM (Plenary of findings in the case studies and closure)	PM 2.2 CM (Plenary of findings in the case studies and closure)

Day	08.00-11.00 am	11.00-12.00 noon	12.00-01.00 pm	1.00-1.30pm	1.30-2.30 pm (L) 1.30-3.30 pm (P)	1.30-2.30 pm (L) 1.30-3.30 pm (P)
55	CP	PA 11.2, 11.3 tumors of childhood, storage disorders (L)	PH 1.42 Cephalosporins (L)	LUNCH BREAK	PA 10.1 Thick & thin smears Malaria (DOAP)	PH 3.1 Prescription writing (P)
56		MI1.11 Immunology of transplant & malignancy(L)	PA 12.2, 12.3 starvation & Obesity (SDL)		PA 10.1 Thick & thin smears Malaria (DOAP)	PH 3.1 Prescription writing (P)
57		MI 8.2 Opportunistic infections (S)	PH 1.50 Immunosuppressants (L)		MI 1.2 Gram staining - I (DOAP)	CM2.1 Clinico Socio-cultural and demographic assessment
58		MI 2.7 HIV(L)	PH 1.42 Aminoglycosides (L)		MI 1.2 Gram staining - I (DOAP)	CM2.1 Clinico Socio-cultural and demographic assessment
59		PH 1.42 Sulfonamides & Quinolones (L)	PM 2.3 MI Sample Collection & Diagnostic test (L)		PA 27.1 Atherosclerosis (L)	PH 1.30 Hypolipidaemics (T)
60		AET-PATH-2.5	PM 2.3 MI Sample Collection, Demo & Hands on (P)		PM 2.3 MI Lab visit & Demo of Diagnostic test (P)	SPORTS

Day	08.00-11.00 am	11.00-12.00 noon	12.00-01.00 pm	1.00-1.30pm	1.30-2.30 pm (L) 1.30-3.30 pm (P)	1.30-2.30 pm (L) 1.30-3.30 pm (P)
61	CP	MI 8.3 Oncogenic viruses (SDL)	PH 1.24 Diuretics (L)	LUNCH BREAK	PA 27.1 Atherosclerosis Gross & M/E (DOAP)	PH 3.2 Prescription Audit (P)
62		MI1.19 Vaccines (I) PE 19.1	PA 27.4 Rheumatic Heart disease (T)		PA 27.1 Atherosclerosis Gross & M/E (DOAP)	PH 3.2 Prescription Audit (P)
63		PH 1.24 Antidiuretics (S)	IM 1.9, 1.27 Rheumatic fever & Rheumatic heart diseases		MI 1.2 Gram staining - II (DOAP)	FM2.32 Demo of law enforcing agency and judiciary practices (P)
64		PA 27.6 Infective Endocarditis (L)	SU 8.1 Ethics in General Surgery (L)		MI 1.2 Gram staining - II (DOAP)	FM2.32 Demo of law enforcing agency and judiciary practices (P)
65		PH 1.26 RAAS (L)	OG8.2 Obstetric history (L)		PA 27.5 IHD (L)	PM 2.3 MI Discussion of Test reports & Choosing a lab test (P)
66	PHARM IA1	CM2.4 Social psychology, Community Behaviour and Community relationship (L)	FM1.7 Legal Procedures (L)		PM 2.3 MI Discussion of Test reports & Choosing a lab test (P)	PM 2.3 MI Discussion & Closure

Day	08.00-11.00 am	11.00-12.00 noon	12.00-01.00 pm	1.00-1.30pm	1.30-2.30 pm (L) 1.30-3.30 pm (P)	1.30-2.30 pm (L) 1.30-3.30 pm (P)
67	MICRO IA1	PA 27.2, 27.3 Aneurysm Heart failure (L)	PH 1.29 Drugs for heart failure (L)	LUNCH BREAK	PA 27.8 IHD lab Interpretation (DOAP)	PH 3.1 Prescription writing (P)
68	PATH IA1	MI 1.1 Blood stream infections (BSII)& CVS Infections- Introduction & Haemorrhagic fevers(L)	PA 27.7 27.9 Pericarditis Cardiomyopathy (L)		PA 27.8 IHD lab Interpretation (DOAP)	PH 3.1 Prescription writing (P)
69	CP	PH 1.27 Anti hypertensives (L)	IM 8.4-8.9, 8.12, 8.15, 2.18 Hypertension & dyspididemia		PATH IA 1 / PHARM IA 1 / MICRO IA 1	
70		MI 2.1 Rheumatic fever (I) GM 1.9	SU 10.1 Common Surgical Procedures (L)			
71		PH 1.27 Anti hypertensives (L)	OG8.4 clinical monitoring of maternal and fetal well-being (L)			



Day	08.00-11.00 am	11.00-12.00 noon	12.00-01.00 pm	1.00-1.30pm	1.30-2.30 pm (L) 1.30-3.30 pm (P)	1.30-2.30 pm (L) 1.30-3.30 pm (P)
72	CP	PA 13.1, 13.2, 14.1, 15.1 Hematopoiesis anticoagulants, Iron, B12 (SDL)	PH 1.27 Drugs for shock (SDL)	LUNCH BREAK	PA13.5 PS Anemia (DOAP)	PH 3.2 Prescription Audit (P)
73		MI 2.2 Infective endocarditis(L)	PA 10.4, 12.1 Infections, tobacco, alcohol (SDL)		PA13.5 PS Anemia (DOAP)	PH 3.2 Prescription Audit (P)
74		PH 1.28 Antiangina drugs (L)	IM 2.1, 2.5, 2.13,2.14, 2.16 Atherosclerosis (L)		MI 2.3 Microbes causing Rheumatic Heart Disease & Infective Endocarditis (DOAP)	FM2.33 Demo of mass disaster management
75		MI 1.1 Plague (T)	SU 12.1 Malnutrition in surgical patients (L)		MI 2.3 Microbes causing Rheumatic Heart Disease & Infective Endocarditis (DOAP)	FM2.33 Demo of mass disaster management
76		PH 1.28 Antiangina drugs (L)	OG12.4 HEART DISEASE IN PREGNANCY(L)		PA 13.3 Classify anemia (L)	MI1.1 BSI-Rickettsia(L)
77		AET-PHAR-2.7	CM8 -3.1 Hazards of pollution		FM1.8 Legal Procedures (L)	SPORTS

Day	08.00-11.00 am	11.00-12.00 noon	12.00-01.00 pm	1.00-1.30pm	1.30-2.30 pm (L) 1.30-3.30 pm (P)	1.30-2.30 pm (L) 1.30-3.30 pm (P)
78	CP	PA 13.4, 14.2 Investigate anemia, Mic Hypo anemia (I) IM, BI	PH 1.28 Antiangina drugs (L)	LUNCH BREAK	PA13.5 PS Anemia (DOAP)	PH 3.3 Drug Promotional lit (P)
79		MI 1.1 BSI & CVS infection-Schistosoma(L)	PA 15.2 Investigate Macro anemia (I) IM, BI		PA13.5 PS Anemia (DOAP)	PH 3.3 Drug Promotional lit (P)
80		PH 1.30 Anti arrhythmic drugs (L)	MI 2.4 Anaemia (I) PA 13.3,GM 9.1		MI 1.2 Gram staining - III (DOAP)	CM B 3.7 Lifecycle of vectors
81		MI 2.5 Kalazar(S)	PH 1.30 Anti arrhythmic drugs (L)		MI 1.2 Gram staining - III (DOAP)	CM A 3.7 Lifecycle of vectors
82		PH 1.35 Haematinics (L)	MI 2.5 Malaria(L)		PA 15.4 Macrocytic anemia DD (I) IM	PM 2.4 BI /CM
83		AET-PHAR-2.7	CM 9 - 3.2 - Water quality standards		FM1.9 Legal Procedures (L)	Feedback & reflection IA 1

Day	08.00-11.00 am	11.00-12.00 noon	12.00-01.00 pm	1.00-1.30pm	1.30-2.30 pm (L) 1.30-3.30 pm (P)	1.30-2.30 pm (L) 1.30-3.30 pm (P)
84	CP	PA 16.1 Introduction to Hemolytic anemia (L)	PH 1.35 Haematinics (L)	LUNCH BREAK	PA 16.6 PS hemolytic anemia (DOAP)	PH 3.3 Drug Promotional lit (P)
85		MI 2.5 Babesia (L)	PA 16.2 Pathogenesis & C/F of Hemolytic anemia (L)		PA 16.6 PS hemolytic anemia (DOAP)	PH 3.3 Drug Promotional lit (P)
86		1.25 Drugs acting on blood (L)	MI 2.5 Filaria (T)		MI 2.6 Identification of Malaria & Filaria (DOAP)	FM2.34 Demo of mass disaster management
87		MI 2.5 Leishmania (SDL)	1.25 Drugs acting on blood (L)		MI 2.6 Identification of Malaria & Filaria (DOAP)	FM2.34 Demo of mass disaster management
88		1.25 Drugs acting on blood (L)	MI 5.1 Infective syndrome causing CNS infection(L)		PA 16.3.1 Sickle cell anemia (L)	PM 2.4 BI /CM
89	PM 2.4 BI /CM	CM10 - 3.3 Water borne diseases	FM1.10 Legal Procedures (L)	SPORTS		

Day	08.00-11.00 am	11.00-12.00 noon	12.00-01.00 pm	1.00-1.30pm	1.30-2.30 pm (L) 1.30-3.30 pm (P)	1.30-2.30 pm (L) 1.30-3.30 pm (P)
90	CP	PA 16.3.2 Thalassemia (L)	PH 1.47 Antimalarials (L)	LUNCH BREAK	PA 14.3, 15.3 Microcytic & macrocytic Anemia PS (DOAP)	PH 3.3 Drug Promotional lit (P)
91		MI 5.1 Pyogenic meningitis-Meningococcus,Pneumococcus,GBS (L)	PA 16.4 Acquired Hemolytic anemia (L)		PA 14.3, 15.3 Microcytic & macrocytic Anemia PS (DOAP)	PH 3.3 Drug Promotional lit (P)
92		PH 1.42 Macrolides (L)	IM16.1-16.3,16.15 Acute Diaphorreal Disease (L)		MI 5.3 Identify microbes causing meningitis (DOAP)	CM B - 3.3Concept of Solid waste diosposal
93		MI 5.1 Pyogenic meningitis-Haemophilus,Listeria & other bacteria (L)	SU 15.1 Hospital waste management (L)		MI 5.3 Identify microbes causing meningitis (DOAP)	CM A - 3.3Concept of Solid waste disposal
94	AET-MIC-2.6	PH 1.42 Broad spectrum antibiotics (T)	OG12.2 ANEMIA IN PREGANCY(L)		PA 16.5 Inves of Hemolytic anemia (T)	PH 1.42 Topical antibiotics (SDL)



Day	08.00-11.00 am	11.00-12.00 noon	12.00-01.00 pm	1.00-1.30pm	1.30-2.30 pm (L) 1.30-3.30 pm (P)	1.30-2.30 pm (L) 1.30-3.30 pm (P)
95	CP	PA 35.1 Meningitis (L)	PH 1.15 SMR (L)	LUNCH BREAK	PA 35.3 Etiology of meningitis (DOAP)	PH 3.1 Prescription writing (P)
96		MI 5.1 Aseptic meningitis - viral (T)	35.2 CNS Tumors (S)		PA 35.3 Etiology of meningitis (DOAP)	PH 3.1 Prescription writing (P)
97		PH 1.17 LA (L)	IM20.8 SCORPION BITE(L)		MI 1.2 AFB staining --I (DOAP)	CM B 4.1 - Methods of HE and advantages
98		MI 5.1 Aseptic meningitis - other causative agents (L)	SU 11.2 General/regional / local anesthesia (L)		MI 1.2 AFB staining --I (DOAP)	CM A 4.1 - Methods of HE and advantages
99		PH 1.18 GA (L)	OG22.1 VAGINAL DISCHARGE(L)		AET-MIC-2.6	
100		AET-CM-2.8	CM11 - 3.6 Role of Vectors and NVBDCP		FM2.1 Causes of death (L)	PM 2.4 BI /CM

Day	08.00-11.00 am	11.00-12.00 noon	12.00-01.00 pm	1.00-1.30pm	1.30-2.30 pm (L) 1.30-3.30 pm (P)	1.30-2.30 pm (L) 1.30-3.30 pm (P)
101	CP	PA 36.1 Retinoblastoma (L)	PH 1.19 Sedative hypnotics (L)	LUNCH BREAK	PA 18.1 WBCs in Smear (DOAP)	PH 4.1 ROA DOAP (P)
102		MI 5.2 Encephalitis - Rabies (T)	PA 18.1 WBC disorders (L)		PA 18.1 WBCs in Smear (DOAP)	PH 4.1 ROA DOAP (P)
103		PH 1.19 Antiepileptics (L)	IM 18.2,18.11-14 CVA(L)		PA 16.7 Cross matching (DOAP)	PH 4.1 ROA DOAP (P)
104		MI 5.2 Encephalitis - Arbo & other viruses (L)	SU 3.1 Blood Transfusion (L)		PA 16.7 Cross matching (DOAP)	PH 4.1 ROA DOAP (P)
105		PH 1.19 drugs for preclampsia (SDL)	OG12.1.2 MANAGEMENT OF HYPERTENSIVE DISORDERS(L)		PA 18.2 Leukemia (L)	MI 5.2 Encephalitis - Toxoplasma & other parasites (SDL)
106		AET-CM-2.8	CM12 - 3.8 - Insecticides and Rodenticides		FM2.2 Natural and unnatural death (L)	SPORTS

Day	08.00-11.00 am	11.00-12.00 noon	12.00-01.00 pm	1.00-1.30pm	1.30-2.30 pm (L) 1.30-3.30 pm (P)	1.30-2.30 pm (L) 1.30-3.30 pm (P)
107	CP	PA 19.2 TB node (L)	PH 1.19 Antidepressants (L)	LUNCH BREAK	PA 19.3 TB gross & M/E (DOAP)	PH 3.6 Interaction with Rep (P)
108		MI 8.1 Zoonotic infections – Leptospira, Borrelia (L)	PA 19.1 Lymphadenopathy (L)		PA 19.3 TB gross & M/E (DOAP)	PH 3.6 Interaction with Rep (P)
109		PH 1.19 Antipsychotics (L)	MI 8.1 Zoonotic infections – Rickettsia (L)		MI 8.7 Infection control practices - Hand hygiene (DOAP)	FM2.35 Demonstration of autopsy techniques
110		PA 19.6, 19.7 Splenomegaly (L)	MI 8.1 Zoonotic infections – Trypanosoma (T)		MI 8.7 Infection control practices - Hand hygiene (DOAP)	FM2.35 Demonstration of autopsy techniques
111		PH 1.19 AntiParkinsonian (L)	MI 1.1 Congenital Infections (T)		PA 20.1 Multiple myeloma (L)	MI 8.4 Emerging & reemerging Infections (L)
112		PA 20.1 Multiple myeloma (DOAP) MI 8.7 PPE (DOAP)	MI 8.5 HAI (L)		PH 1.19 Opioids (L)	PM 2.5 PH /IM Drug development, CT during pandemic

Day	08.00-11.00 am	11.00-12.00 noon	12.00-01.00 pm	1.00-1.30pm	1.30-2.30 pm (L) 1.30-3.30 pm (P)	1.30-2.30 pm (L) 1.30-3.30 pm (P)
113	CP	PA 19.4 Hodgkin's vs Non Hodgkin's Lymphoma (L)	PH 1.19 Opioids (L)	LUNCH BREAK	PA 19.5 Hodgkin's Lymphoma (DOAP)	PH 3.6 Interaction with Rep (P)
114		MI 8.6 Basics of infection control (T)	PA 19.5 Hodgkin's Lymphoma (T)		PA 19.5 Hodgkin's Lymphoma (DOAP)	PH 3.6 Interaction with Rep (P)
115		PH 1.19 Antianxiety, antimania (S)	IM17.1,17.3 TYPES OF HEADACHE & MIGRAINE		MI 8.7 PPE (DOAP)	CM B - 4.2 - Counselling activities to individual and family
116		PA 17.1, 17.2,21.1 Aplastic anemia/ Hemostasis (SDL)	SU 17.5 Neurological assesment in head injuries (L)		MI 1.2 AFB staining --II (DOAP)	CM A - 4.2 - Counselling activities to individual and family
117		1.19 CNS stimulants (S)	OG23.1 NORMAL AND ABNORMAL PUBERTY(L)		PA 21.2, 21.3 ITP, clotting disorders (L)	MI 8.8 Microbial contamination of food,water&air (S)
118		PA 20.1 Multiple myeloma (DOAP) MI 1.2 AFB staining --II (DOAP)	CM13 - 4.3 Health promotion and Education program		FM2.3 Sudden death (L)	SPORTS

Day	08.00-11.00 am	11.00-12.00 noon	12.00-01.00 pm	1.00-1.30pm	1.30-2.30 pm (L) 1.30-3.30 pm (P)	1.30-2.30 pm (L) 1.30-3.30 pm (P)
119	CP	PA 21.4 DIC (L)	PH 1.32 Drugs for bronchial asthma (L)	LUNCH BREAK	PA 22.2 compatibility testing(SGD)	PH 3.8 Communicate medication use (P)
120		MI 6.1 Infective syndrome of Respiratory tract (L)	PA 21.5 vitamin K deficiency (T)		PA 22.2 compatibility testing(SGD)	PH 3.8 Communicate medication use (P)
121		PH 1.32 Drugs for COPD (SDL)	IM3.1,3.15,3.17 Pneumonia		MI 6.2 Identify agents causing URTI -I (DOAP)	FM3.32 Demonstration of autopsy techniques
122		PA 26.1 26.2 Pneumonia & Lung abscess(L)	SU 17.9 Clinical features and management of chest injuries (L)		MI 6.2 Identify agents causing URTI -I (DOAP)	FM3.32 Demonstration of autopsy techniques
123		PH 1.33 Drugs for cough (T)	OG12.8 ISOIMMUNIZATION IN PREGNANCY(L)		PA 22.1, 22.4, 22.7 Blood group, components & Autologous transfusion (SDL)	MI 6.1 URTI-Diphtheria(L)

Day	08.00-11.00 am	11.00-12.00 noon	12.00-01.00 pm	1.00-1.30pm	1.30-2.30 pm (L) 1.30-3.30 pm (P)	1.30-2.30 pm (L) 1.30-3.30 pm (P)
124	CP	PA 26.3 COPD (L)	PH 1.44 Antituberculosis drugs (L)	LUNCH BREAK	PA 26.1 Peumonia(DOAP)	PH 3.8 Communicate medication use (P)
125		MI 6.1 URTI-GAS(L)	PA 26.4 TB (T)		PA 26.1 Peumonia(DOAP)	PH 3.8 Communicate medication use (P)
126		PH 1.45 Drugs in MDR, XDR TB (T)	IM14.5,14.13 Nutritional Disorders		MI 6.2 Identify agents causing URTI -II (DOAP)	CM B - 5.1 Nutritional requirements
127		PA 26.5 Pneumoconiasis (L)	SU 12.2 Fluid and electrolyte requirements in surgical patient (L)		MI 6.2 Identify agents causing URTI -II (DOAP)	CM A - 5.1 Nutritional requirements
128		PH 1.46 Antileprotic drugs (L)	OG27.2 GENITAL TB(L)		PA 26.6 Lung & Pleura tumors (L)	MI 6.1 URTI-Orthomyxovirus(L)
129		PH 3.5 Prepare P drug list (P) /PA 26.3 COPD (DOAP)	CM 14		FM2.4 Organ transplantation act	SPORTS

Day	08.00-11.00 am	11.00-12.00 noon	12.00-01.00 pm	1.00-1.30pm	1.30-2.30 pm (L) 1.30-3.30 pm (P)	1.30-2.30 pm (L) 1.30-3.30 pm (P)
130	CP	PA 26.7 Mesothelioma (SDL)	PH Dermatological drugs (L)	LUNCH BREAK	PA 34.4 Tumors of skin (DOAP)	PH 3.5 Prepare P drug list (P)
131		MI 6.1 URTI-Other viruses & fungi (L)	PA 34.1 Squamous cell Ca (L)		PA 34.4 Tumors of skin (DOAP)	PH 3.5 Prepare P drug list (P)
132		PH 1.58 Ocular drugs (T)	MI 6.1 LRTI - Pneumococcus, Klebsiella (L)		MI 6.3 Identify agents causing LRTI -I (DOAP)	FM3.33 Demonstration of examination of of torture and human right violations, sexual assaultpsychological consultation, rehabilitation
133		PA 34.2 Basal Cell Ca (L)	MI 6.1 LRTI - Haemophilus,Bordetella (T)		MI 6.3 Identify agents causing LRTI -I (DOAP)	FM3.33 Demonstration of examination of of torture and human right violations, sexual assaults psychological consultation, rehabilitation
134		PH 1.56 Paediatric/ Geriatric drugs (T)	MI 6.1 LRTI - TB (I) PA 26.4, CT 1.2		PA 34.3 Naevus & melanoma (L)	MI 6.1 Non-tuberculous Mycobacteria (SDL)
135		PH 3.5 Prepare P drug list (P) /PA 26.3 COPD (DOAP)	CM 15 - 5.3.1 - Nutritional disorders		FM2.5 Death and its causes	PM 2.5 PH /IM New Drug development challenges, solutions

Day	08.00-11.00 am	11.00-12.00 noon	12.00-01.00 pm	1.00-1.30pm	1.30-2.30 pm (L) 1.30-3.30 pm (P)	1.30-2.30 pm (L) 1.30-3.30 pm (P)
136	CP	PA 29.1 Testicular tumor (L)	PH 1.38 Corticosteroids (L)	LUNCH BREAK	PA 29.1 Seminoma (DOAP)	PH 3.5 Prepare P drug list (P)
137		MI 6.1 Atypical pneumonia- Chlamydia, Mycoplasma, Legionella (L)	PA 29.2 Ca Penis (L)		PA 29.1 Seminoma (DOAP)	PH 3.5 Prepare P drug list (P)
138		PH 1.37 Pitutary hormones (L)	IM12.11Thyroid Disorders		MI 6.3 Identify agents causing LRTI -II (DOAP)	CM B - 5.4 Recommend diet in a simulated environment
139		PA 29.3, 29.4 Benign prostatic hyperplasia & ca (L)	SU11.6 Principles of safe general surgery (L)		MI 6.3 Identify agents causing LRTI -II (DOAP)	CM A - 5.4 Recommend diet in a simulated environment
140		PH 1.37 Estrogen, progestin (L)	OG21.1 CONTRACEPTION (L)		PA 29.5 Prostitis (SDL)	PH 1.39 Contraceptives (T)
141		MI 1.2 AFB staining-III (DOAP) / PH 5.1 Communicate with empathy (P)	CM 16 - 5.3.2 - Nutritional disorders		FM2.6 Presumption of death and survivorship	SPORTS



Day	08.00-11.00 am	11.00-12.00 noon	12.00-01.00 pm	1.00-1.30pm	1.30-2.30 pm (L) 1.30-3.30 pm (P)	1.30-2.30 pm (L) 1.30-3.30 pm (P)
142	CP	PA 30.1 Ca Cervix (I) OG	PH 1.40 Antiandrogens (L)	LUNCH BREAK	PA 29.3, 30.1 BPH, Pap smear (DOAP)	PH 5.1 Communicate with empathy (P)
143		MI 6.1 Paramyxovirus, Coronavirus (L)	PA 30.1 Ca Cervix (I) CM		PA 29.3, 30.1 BPH, Pap smear (DOAP)	PH 5.1 Communicate with empathy (P)
144		PH 1.41 Drugs acting on uterus (S)	IM10.1 AKI & CKD		MI 1.2 AFB staining --III (DOAP)	FM4.28 Updates of code of medical practice and ethics
145		PHARM IA 2	PA 30.1 Ca Cervix (I) PA		SU1.3 Perioperative care	MI 1.2 Gram staining --IV (DOAP)

Day	08.00-11.00 am	11.00-12.00 noon	12.00-01.00 pm	1.00-1.30pm	1.30-2.30 pm (L) 1.30-3.30 pm (P)	1.30-2.30 pm (L) 1.30-3.30 pm (P)
146	MICRO IA 2	PA 30.2, 30.3 EM/ myometrium (L)	PH 1.49 Anticancer drugs (L)	<b>LUNCH BREAK</b>	PA 30.2 EM phases (DOAP)	PH 5.1 Communicate with empathy (P)
147	PATH IA 2	MI 6.1 LRTI- fung i& parasites (L)	PA 30.4 Ovarian tumors (L)		PA 30.2 EM phases (DOAP)	PH 5.2 Optimal use of drug (P)
148	CP	PH 1.49 Anticancer drugs (L)	IM7.3,7.14, 7.19 Approach to Joint pain		<b>PATH IA 2 / PHARM IA 2 / MICRO IA 2</b>	
149		PA 30.5 Gestational trophoblastic diseases (S)	SU10.1 Common surgical procedures			
150		PH 1.49 Anticancer drugs (L)	OG34.3 Gestational trophoblastic diseases(L)			
151		MI 1.2 Gram staining --IV (DOAP) /PH 5.2 Optimal	CM 17 - 5.5 - Nutritional surveillance			FM2.7 Suspended animation



Day	08.00-11.00 am	11.00-12.00 noon	12.00-01.00 pm	1.00-1.30pm	1.30-2.30 pm (L) 1.30-3.30 pm (P)	1.30-2.30 pm (L) 1.30-3.30 pm (P)
152	CP	PA 30.6 cervicitis (SDL)	PH 1.20 Alcohol (L)	LUNCH BREAK	PA 30.5 Gestational Trophoblastic Diseases (DOAP)	PH 5.2 Optimal use of device (P)
153		MI 7.1 Infection syndrome of Genitourinary system (L)	PA 30.7 30.8 30.9 Endometriosis (L)		PA 30.5 Gestational Trophoblastic Diseases (DOAP)	PH 5.2 Optimal use of device (P)
154		PH 1.21 Alcohol poisoning (T)	MI 7.2 Syphilis (I)DR 10.3		MI 7.2 Diagnosis of STD (P)	FM4.29 Demonstration of interaction with public, Media
155		PA 27.10 Syphilis (SDL)	MI 7.2 Chlamydia (LGV,GI),Uroplasma (SDL)		MI 7.2 Diagnosis of STD (P)	FM4.29 Demonstration of interaction with public, Media
156		PH 1.22 Drugs of abuse (L)	MI 7.2 Gonococci,H.ducreyi,Bacterial vaginosis,L)		PA 31.1, 31.4 Benign breast disease (L)	PH 1.23 Drug deaddiction (SDL)
157		MI 7.2 Trichomonas vaginalis (T)	CM 18 - 5.6 - Nutritional policy, ICDS		FM2.8 Early postmortem changes	Feedback & reflection IA 2

Day	08.00-11.00 am	11.00-12.00 noon	12.00-01.00 pm	1.00-1.30pm	1.30-2.30 pm (L) 1.30-3.30 pm (P)	1.30-2.30 pm (L) 1.30-3.30 pm (P)
158	CP	PA 31.2 Ca breast (L)	PH 1.34 Drugs for APD (L)	LUNCH BREAK	PA31.3 Gross & M/E Ca Breast (DOAP)	PH 5.2 Optimal use of storage of medicine (P)
159		MI 7.2 Candida (L)	PA 24.1 Oral cancers (S)		PA31.3 Gross & M/E Ca Breast (DOAP)	PH 5.2 Optimal use of storage of medicine (P)
160		PH 1.34 Antiemetics (L)	MI 7.2 HSV (L)		MI 7.3 Diagnosis of UTI (P)	CM B - 5.7 and 5.8 - Food hygiene, fortification
161		PA 24.2 Peptic Ulcer (L)	PH 1.34 Antidiarrhoeals (L)		MI 7.3 Diagnosis of UTI (P)	CM A - 5.7 and 5.8 - Food hygiene, fortification
162		PH 1.34 Drugs for IBD, IRB (T)	MI 7.2 HPV (S)		PA 24.4 Ca stomach (L)	CM 28 - SDL
Day	08.00-11.00 am	11.00-12.00 noon	12.00-01.00 pm	1.00-1.30pm	1.30-2.30 pm (L) 1.30-3.30 pm (P)	1.30-2.30 pm (L) 1.30-3.30 pm (P)
163	CP	PA 24.6 Inflammatory bowel Disease (L)	PH 1.34 water borne diseases (SDL)	INCH BREAK	PA 24.3 Gross & M/E Peptic Ulcer (T)	PH 4.2 CAL (P)
164		MI 27.3 UTI(T)	PA 24.7 Ca colon (I) SU		PA 24.3 Gross & M/E Peptic Ulcer (T)	PH 4.2 CAL (P)
165		PH 1.34 Retrieve drug info (SDL)	IM5.16 Hepatitis		PA 24.5 TB intestine (T)	PH 4.2 CAL (P)

166		PA 25.1 Hyperbilirubinemia (SDL)	PA 24.7 Ca colon (I) SU 28.13 Applied anatomy of large intestine	LU	PA 24.5 TB intestine (T)	PH 4.2 CAL (P)
167		PH 1.47 Antiamoebic (T)	OG12.7 HIV IN MOTHER(L)		PA 25.2 Hepatic failure (L)	PH 1.47 Antihelminthic (T)
<b>Day</b>	<b>08.00-11.00 am</b>	<b>11.00-12.00 noon</b>	<b>12.00-01.00 pm</b>	<b>1.00-1.30pm</b>	<b>1.30-2.30 pm (L) 1.30-3.30 pm (P)</b>	<b>1.30-2.30 pm (L) 1.30-3.30 pm (P)</b>
168	CP	PA 25.3.1 Hepatitis (I) Path	PH 1.47 Protozoal disease (SDL)	LUNCH BREAK	PA 25.3 Hepatitis (DOAP)	PH 3.1 Prescription writing (P)
169		MI 3.1 Infective syndrome of GIT (L)	PA 25.3.1 Hepatitis (I) Micro		PA 25.3 Hepatitis (DOAP)	PH 3.1 Prescription writing (P)
170		PH 1.48 Antiviral (L)	IM6.1-6.3, 6.11-6.12 HIV		PM 2.5 PH /IM ADR monitoring exercises in wards	
171	MI 3.1 Salmonella & Shigella (L)	CM 19 - 7.2.1 - Modes of transmission, Prevention of CD	FM2.9 Late postmortem changes	LUNCH BREAK	SPORTS	
<b>Day</b>	<b>08.00-11.00 am</b>	<b>11.00-12.00 noon</b>	<b>12.00-01.00 pm</b>	<b>1.00-1.30pm</b>	<b>1.30-2.30 pm (L) 1.30-3.30 pm (P)</b>	<b>1.30-2.30 pm (L) 1.30-3.30 pm (P)</b>
172		PA 25.3.1 Hepatitis (I) IM	PH 1.48 Antiretroviral (L)		PA 25.6 Jaundice - LFT (DOAP)	PH 3.2 Prescription audit (P)
173		MI 3.1 Vibrio (L)	PA 25.4 Alcoholic Liver disease (L)		PA 25.6 Jaundice - LFT (DOAP)	PH 3.2 Prescription audit (P)

174	CP	PH 1.48 Drugs for COVID (SDL)	IM10.5,10.8 Nephritic & Nephrotic Syndrome
175		PA 25.5 Portal HT (L)	SU16.1 Minimally invasive general surgery
176		PH 1.61 Vitamins (S)	OG12.6 LIVER DISEASE IN PREGNANCY(L)
177	PA 28.1 Kidney histology (SDL)	CM 20 - 7.2.2 - Modes of transmission, Prevention of CD	FM2.10 Estimation of time since death

LUNCH BREAK

MI 3.2 Diagnosis of GIT infections (DOAP)	CM B - 8.1.1 CSC - ARI
MI 3.2 Diagnosis of GIT infections (DOAP)	CM A - 8.1.1 CSC - ARI
PA 28.2 Renal failure (L)	PH 1.48 Antifungal (L)
SPORTS	



Day	08.00-11.00 am	11.00-12.00 noon	12.00-01.00 pm	1.00-1.30pm	1.30-2.30 pm (L) 1.30-3.30 pm (P)	1.30-2.30 pm (L) 1.30-3.30 pm (P)
178	CP	PA 28.3, 28.4 Acute & chronic renal failure (L)	PH 1.48 Topical drugs (SDL)	LUNCH BREAK	PA 28.5 Urine examination - Physical (D)	PH 5.3 Motivate patients (P)
179		MI 3.1 Diarrhogenic E.coli & H.pylori, Campylobacter, Yersinia (L)	PA 28.5 Glomerulonephritis (L)		PA 28.5 Urine examination - Physical (D)	PH 5.3 Motivate patients (P)
180		PH 1.48 Drugs for UTI/STD (T)	IM5.16.1 Cirrhosis complications & Management		MI 1.2 Stool microscopy-I (DOAP)	FM4.30 Demonstratio of research guidelines
181		PA 28.6 IgA nephropathy (L)	SU 29.1 Management of hematuria		MI 1.2 Stool microscopy-I (DOAP)	FM4.30 Demonstratio of research guidelines
182		PH 1.53 Chelating agents (S)	OG 12.5 UTI IN PREGNANCY (L)		PA 28.7 Systemic diseases - Renal manifestation (S)	CM 27 - SDL - 8.1.2 - ARI symptoms and management

183	PA 28.5 Urine examination - Protein (D)/ PH 5.3 Motivate patients (P)	CM 21 - SDL - 7.2.3 - ID epidemiology - Definitions	MI 3.1 Viral gastroenteritis (S)		SPORTS	
Day	08.00-11.00 am	11.00-12.00 noon	12.00-01.00 pm	1.00-1.30pm	1.30-2.30 pm (L) 1.30-3.30 pm (P)	1.30-2.30 pm (L) 1.30-3.30 pm (P)
184	CP	PA28.8, 28.9 Tubular pathology (L)	PH 1.51 Pollutants (T)	LUNCH BREAK	PA 28.5 Urine examination - sugar (DOAP)	PH 5.3 Motivate patients (P)
185		MI 3.1 Amoeba (L)	PA 28.10 Pyelonephritis (L)		PA 28.5 Urine examination - sugar (DOAP)	PH 5.4 Cost of tretment (P)
186		PH 1.52 Poisons (T)	IM21.1 Approach to patient stabilising in poisoning		MI 1.2 Stool microscopy-II (DOAP)	CM B - 7.2.4 - Sources and Reservoirs
187	CP	PH 1.63 Drug acts (S)	OG 24.1 ABNORMAL UTERINE BLEEDING (L)	LUNCH BREAK	MI 1.2 Stool microscopy-II (DOAP)	CM A - 7.2.4 - Sources and Reservoirs
188	PA 28.5 Urine examination - Protein (D)/ PH 5.4 Cost of tretment (P)	CM 22 - SDL - 1.3 Disease causation and Multifactorial etiology		LUNCH BREAK	SPORTS	
Day	08.00-11.00 am	11.00-12.00 noon	12.00-01.00 pm	1.00-1.30pm	1.30-2.30 pm (L) 1.30-3.30 pm (P)	1.30-2.30 pm (L) 1.30-3.30 pm (P)
189		PA 28.11 vascular diseases of kidney (L)	PH 1.55 NHP (T)		PA 28.13 Obstructive uropathy (DOAP)	PH 5.4 Cost of tretment (P)

190	CP	MI 3.1 Coccidian parasites & Microsporidia (SDL)	PA 28.12 cystic diseases of kidney (L)	LUNCH BREAK	PA 28.13 Obstructive uropathy (DOAP)	PH 5.4 Cost of treatment (P)
191		PH 1.55 NHP (T)	IM4.6 Malaria		MI 1.2 Stool microscopy-III (DOAP)	FM6.3 Demonstrating preservation of evidences sent to FSL
192		PA 28.13 Obstructive uropathy (L)	SU 29.3 Management of UTI (L)		MI 1.2 Stool microscopy-III (DOAP)	FM6.3 Demonstrating preservation of evidences sent to FSL
193		PH 1.62 Antiseptics (T)	OG 29.1 UTERINE FIBROIDS (L)		PA 28.14 renal tumors (L)	CM29 - SDL - 8.1.3 - Epidemiology of Small pox and Chicken pox
<b>Day</b>	<b>08.00-11.00 am</b>	<b>11.00-12.00 noon</b>	<b>12.00-01.00 pm</b>	<b>1.00-1.30pm</b>	<b>1.30-2.30 pm (L) 1.30-3.30 pm (P)</b>	<b>1.30-2.30 pm (L) 1.30-3.30 pm (P)</b>
194	CP	PA 28.15 Thrombotic angiopathy (L)	PH 1.36 Drugs affecting Calcium (T)	LUNCH BREAK	PA 28.14 renal tumors (DOAP)	PH 5.5 Caution in prescribing drug (P)
195		MI 3.1 Intestinal Cestodes (L)	PA 28.16 Urothelial tumors (L)		PA 28.14 renal tumors (DOAP)	PH 5.5 Caution in prescribing drug (P)
196		PH 1.36 Osteoporosis (SDL)	MI 3.1 Intestinal Trematodes (L)		MI 1.2 Stool microscopy-IV (DOAP)	CM B - 8.1.4 - CSC - Fever with rash
197		PA 32.1, 32.2 Thyroid swelling, Thyrotoxicosis (L)	SU22.2 Thyroid swellings (SDL)		MI 1.2 Stool microscopy-IV (DOAP)	CM A - 8.1.4 - CSC - Fever with rash



198		PH 1.36 Antithyroid drugs (L)	OG 13.1 PHYSIOLOGY AND MECHANISM OF LABOUR(L)		PA 32.3, 32.5 Hyper hypo thyroidism &Hyperparathyroidism (L)	CM30 - SDL - 8.1.5 TB (1)
199	PH 3.7 Prepare EML (I) CM 19.1 (P)	CM 23 - SDL 8.1.6 - Mumps, Measles and Rubella	MI 3.1 Intestinal Nematodes-I (L)		SPORTS	
<b>Day</b>	<b>08.00-11.00 am</b>	<b>11.00-12.00 noon</b>	<b>12.00-01.00 pm</b>	<b>1.00-1.30pm</b>	<b>1.30-2.30 pm (L) 1.30-3.30 pm (P)</b>	<b>1.30-2.30 pm (L) 1.30-3.30 pm (P)</b>
200	CP	PA 32.4 Diabetes (L)	PH 1.36 OHA (L)	<b>LUNCH BREAK</b>	PA 32.4 Diabetes - Urine Ketones (DOAP)	PH 5.5 Caution in prescribing drug (P)
201		MI 3.1 Intestinal Nematodes-II (L)	PA 32.6 - Pancreas Pathology (SDL)		PA 32.4 Diabetes - Urine Ketones (DOAP)	PH 5.5 Caution in prescribing drug (P)
202		PH 1.36 Insulin (L)	MI 3.3 Enteric fever (L)		MI 3.4 Diagnosis of enteric fever (DOAP)	FM14.1 Examine and prepare Medico-legal report of an injured person
203		PA 32.9 Adrenal neoplasm (S)	MI 3.6 Food poisoning (T)		MI 3.4 Diagnosis of enteric fever (DOAP)	FM14.1 Examine and prepare Medico-legal report of an injured person
204		PH 1.54 Vaccines (T)	OG 8.7 VACCINATION IN PRENANCY(L)		PA 33.1 Osteomyelitis (L)	MI 3.6 APD (SDL)
205		MI 3.8 Diagnosis of viral hepatitis (P) / PH 5.5 Caution in prescribing drug (P)	CM 24 - 8.1.7 - TB (2)		PH !.64 GCP (L)	SPORTS

Day	08.00-11.00 am	11.00-12.00 noon	12.00-01.00 pm	1.00-1.30pm	1.30-2.30 pm (L) 1.30-3.30 pm (P)	1.30-2.30 pm (L) 1.30-3.30 pm (P)
206	CP	PA 33.2 Bone tumors Benign (L)	PH 1.14 Oraganophosphorus, Myasthenia management (T)	LUNCH BREAK	PA 33.2 Bone tumors Gorss & M/E (DOAP)	PH 5.5 Caution in prescribing drug (P)
207		MI 3.7 Hepatitis viruses (I) PA 25.3, IM 5.4	PA 33.2 Bone tumors - Sarcoma(L)		PA 33.2 Bone tumors Gorss & M/E (DOAP)	PH 5.6 Educate patient on drug use (P)
208		PH 1.62 Disinfectants (L)	MI 3.7 Hepatitis B (L)		MI 3.8 (A Batch) Diagnosis of viral hepatitis (P)	MI 1.5 (B Batch)Applicatiopn of sterilisation & disinfection- OSPE
209		PA 33.4 Paget's Disease bone (L)	MI 3.7 Parasites causing hepatitis (L)		MI 4.1 (B Batch) Diagnosis of Anaerobic infections (P)	MI 1.5 (A Batch)Applicatiopn of sterilisation & disinfection- OSPE
210		PH 1.60 PE exercises (T)	OG 14.1,14.2 DIAMETERS OF MATERNAL PELVIS AND TYPES, LABOUR(L)		PA 33.5 Rheumatoid arthritis (T)	MI 4.1 Anaerobic Infections (T)
211		MI4.1 Diagnosis of Anaerobic infections (P)/ PH 5.6 Educate patient on drug use	CM 25 - SDL - 8.1.8 - SARS and COVID		PH 1.60 PE exercises (T)	SPORTS
Day	08.00-11.00 am	11.00-12.00 noon	12.00-01.00 pm	1.00-1.30pm	1.30-2.30 pm (L) 1.30-3.30 pm (P)	1.30-2.30 pm (L) 1.30-3.30 pm (P)
212		PA 33.3 .1 Soft tissue tumors Benign (L)	PH 1.37 Drugs for pregnancy, lactation (L)		PA 33.3.1 Soft tissue tumors - Benign (DOAP)	PH 5.6 Educate patient on drug use (P)

213	CP	MI 4.2 Bone & Joint Infections (L)	PA 33.3 Soft tissue tumors - sarcoma (L)
214		PH 1.52 Toxoids, Immunoglobulins (L)	MI 4.3 SSTI-Staphylococcus (L)
215	PA 33.3.2 Soft tissue tumors - Malignant/MI 4.3 Diagnosis of SSTI (P)	PA 32.7 Adrenal Insufficiency (L)	MI 4.3 SSTI-Streptococcus, Anthrax (T)
216	PA 33.3.2 Soft tissue tumors - Malignant / MI 8.10 Sample collection (DOAP)	1.4 Pharmacokinetics Revision (T)	MI 4.3 Clostridium-gas gangrene (L)

LUNCH BREAK

PA 33.3.1 Soft tissue tumors - Benign (DOAP)	PH 5.6 Educate patient on drug use (P)
MI 4.3 (A Batch)Diagnosis of SSTI (P)	MI 3.8 (B Batch) Diagnosis of viral hepatitis- OSPE
MI 8.10 (B Batch)Sample collection (DOAP)	MI 3.8 (A Batch) Diagnosis of viral hepatitis- OSPE
PA 32..8 .1 Cushing's syndorme (L)	PA 32.8.2 - Investigation of endocrine disorders (L)



Day	08.00-11.00 am	11.00-12.00 noon	12.00-01.00 pm	1.00-1.30pm	1.30-2.30 pm (L) 1.30-3.30 pm (P)	1.30-2.30 pm (L) 1.30-3.30 pm (P)
217	PH 5.6 Educate patient on drug use (P) /PA	PA 4.1, 4.4 - Inflammation revision(L)	PH 1.5 Pharmacodynamics Revision (T)	BREAK	PA 13.5 Peripheral smear (DOAP) revision	PH 5.6 Educate patient on drug use (P)
218	PH 5.7 Legal aspects of drug prescribing (P) /PATH P	MI 4.3 Non-sporing Anaerobes (L)	PA 7.1, 7.5 Neoplasia revision (T)		PA 13.5 Peripheral smear (DOAP) revision	PH 5.7 Legal aspects of drug prescribing (P)
219	PH 5.7 Legal aspects of drug prescribing (P) / MI 8.11Demonstrate respect for samples (DOAP)	PH 1.14 Cholinergic system Revision (S)	MI 4.3 Non-fermenters (SDL)		MI 8.11 (A Batch)Demonstrate respect for samples (DOAP)	MI 1.2 (B Batch)Gram staining,AFB staining,Stool microscopy (Revision)

220	PH 5.7 Legal aspects of drug prescribing (P) / M 8.15 Interpretation of lab results(P)	PA 3.1, 3.2 Amyloidosis revision (T)	MI 4.3 Pox virus (T)
221	PA 4.4, 7.1 Inflammation & anemia (DOAP)/ MI 8.4 Confidentiality in results (DOAP)	PH 1.13 Adrenergic system Revision (T)	MI 4.3 SSTI- HSV & other viruses(S)
222	PA 4.4, 7.1 Inflammation & anemia (DOAP)/ MI 8.14 Confidentiality in results (DOAP)	MI 4.3 SSTI-Parasites (L)	CM26

LUNCH BF

MI 8.115 (B Batch) Interpretation of lab results (P)	(MI 1.2 (A Batch) Gram staining, AFB staining, Stool microscopy (Revision)
PA 14.2 Microcytic anemia (DOAP) - revision	PA 15.2 Macrocytic anemia (DOAP) - revision
SPORTS	



Day	08.00-11.00 am	11.00-12.00 noon	12.00-01.00 pm	1.00-1.30pm	1.30-2.30 pm (L) 1.30-3.30 pm (P)	1.30-2.30 pm (L) 1.30-3.30 pm (P)
223	MI 8.9 Sample collection (L)	PA 19.4 Hodgkin's vs Non Hodgkin's Lymphoma revision (L)	PH 1.42 Cell wall synthesis inhibitors Revision (T)	LUNCH BREAK	PA 19.5 Hodgkin's Lymphoma (DOAP) revision	PH 4.1 ROA DOAP (P)
224	PA 21.4 DIC Revision (L)	MI 4.3 SSTI- Candida & other fungi (L)	PH 1.42 Protein synthesis inhibitors Revision (S)		PA 19.5 Hodgkin's Lymphoma (DOAP) revision	PH 4.1 ROA DOAP (P)
225	PHARM IA 3	PH 1.24 Drugs affecting Kidney Revision (S)	MI 8.12 Confidentiality in lab results (L)		PA 22.4 Ca stomach (DOAP) Revision	PH 3.2 Prescription auditing (P)
226	MICRO IA 3	PH 1.28, 29 Drugs affecting CVS Revision (T)	MI 8.13 Choose the appropriate test (T)		PA 22.4 Ca stomach (DOAP) Revision	PH 3.2 Prescription auditing (P)

227	PATH IA3	PA 22.4 Ca stomach (L) Revision	MI 8.16 National Health Programmes (I) CM 17.4	PH 3.1 Prescription writing (P)		
Day	08.00-11.00 am	11.00-12.00 noon	12.00-01.00 pm	1.00-1.30pm	1.30-2.30 pm (L) 1.30-3.30 pm (P)	1.30-2.30 pm (L) 1.30-3.30 pm (P)
228				LUNCH BREAK	PATH IA 3 / PHARM IA 3 / MICRO IA 3	
228						
228						
228						
228						